View Single Post
Old 09-15-2008, 03:57 PM   #10
fullofbeans
Senior Member
 
Join Date: Jan 2007
Location: UK
Posts: 617
Thanks Rich66 for posting.

I think it looks fantastic and from trustworthy scientific publication house.

The serum factor vitamin D3 binding protein (also called a Gc protein) is a naturally-produced molecule with a sugar component and a protein component. It is an abundant glyco-protein found in human blood serum [1]

What has been found a while ago [2] is that macrophage activating factor (GcMAF) was formed from vitamin D3 -binding protein. GcMAF greatly enhance phagocytic activity (i.e. immune cells killing ability).

Cancer cells secrete an enzyme known as alpha-N-acetylgalactosaminidase (also called Nagalase) that completely blocks conversion of Gc protein to MAF and therefore the cancer cells escape destruction by the immune system. But also makes people weaker and more susceptible to infection..

Anyhow what they can do (in the lab) is to transform the Gc protein (by stepwise incubation with 2 different enzyme) to produce GcMAF. Then they innoculate this enzymatically generated macrophage activating factor directly into the animal/human.

Ok I have not read the paper yet but it looks awesome what I am uncertain about is how the immune system knows what to destroy i.e. recognition of cancer cell is an issue and the founding principle of this her2 group i.e over expressing Her2 protein. But hey I could do with some GcMAF with my herceptin I reckon..

Best wishes

1-"The Gc protein (human group-specific component (Gc), a vitamin D-binding protein or Gc globulin), has important physiological functions that include involvement in vitamin D transport and storage, scavenging of extracellular G-actin, enhancement of the chemotactic activity of C5a for neutrophils in inflammation and macrophage activation (mediated by a GalNAc-modified Gc protein (GcMAF)"
2- http://www.nature.com/icb/journal/v7...icb199833a.pdf
__________________

35 y/o
June 06: BC stage I
Grade 3; ER/PR neg
Her-2+++; lumpectomies

Aug 06: Stage IV
liver mets: 6 tumours
July 06 to Jan 07: 2*FEC+6*Taxotere; 3*TACE; LITT
March 07- Sept 07: Vaccination trial (phase 2, peptide based) at the UW (Seattle).
Herceptin since 2006
NED til Oct 09
Recurrence Oct 2009: to internal mammary gland since October 2009 missed on Oct and March 2010 scan.. palpable nodes in May 2010 when I realised..
Nov 2011:7 mets to lungs progressing fast failed hercp/tykerb/xeloda combo..

superior vena cava blocked: stent but face remains puffy

April 2012: Teresa Trial, randomised to TDM1
Nov 2012 progressing on TDM1
Dec 2012 blockage of my airways by tumours, obliteration of these blocking tumours breathing better but hoping for more- at mo too many tumours to count in the lungs and nodes.

Dec 2012 Starting new trial S-222611 phase 1b dual egfr her2+ inhibitor.



'Under no circumstances should you lose hope..' Dalai Lama
fullofbeans is offline   Reply With Quote